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Abstract Eleetrospray mass spectrometry coupled to liquid 
chromatography was utilized to measure two PKC neuronal 
substrates, B-501GAP-43 and neurogranin, in single rat brain 
areas. Aliquots of perchloric acid extracts were directly injected 
and mass spectra recorded. At elution times of 14.2 and 27.0 min 
two molecular species of MW 7450 and 23602 Da were 
observed. These values are in excellent agreement for the 
expected MW for rat neurogranin and B-S01GAP-43. The 
presence of molecular species shifted by 80 mass units in both 
cases indicates that these proteins are present in phosphorylated 
forms in cortical and hippocampal extracts. 
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1. Introduction 
In the central nervous ystem (CNS), protein kinases play a 
key role in the postreceptor p ocessing of extracellular signals 
by phosphorylating specific protein substrates [1]. The role 
played by phosphorylation of individual proteins in these 
processes has been mainly inferred from in vitro experiments 
measuring their degree of phosphorylation by procedures in- 
volving back-titration to label residual phosphorylatable sites 
by means of phosphate incorporation from 32p-labelled ATP 
[1]. The degree of phosphorylation in vitro is therefore 
thought o represent the number of non-phosphorylated sites 
in vivo. An alternative to this post-hoc phosphorylation assay, 
which more closely measures the degree of phosphorylation in 
vivo, involves in situ labelling of the proteins by incubating 
intact tissues with 32p and subsequent immunoprecipitation of 
the protein of interest (for instance, see [2]). 
A more recent technique involves the use of antibodies 
raised against specific phosphopeptides [3]. However, also 
this approach does not allow for the simultaneous measure- 
ment of both phospho and dephospho forms. Therefore, all 
these methods are indirect and are not able to detect in the 
same sample and with the same sensitivity each of the two 
forms of the protein independently. 
On the basis of these observations, there is clearly a need 
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for a better method to determine directly the phosphorylation 
state of a protein, particularly at low concentration levels in 
complex systems and at present he most suitable technique 
for this purpose is electrospray mass spectrometry (ES/MS). 
ES/MS allows for determining the molecular mass of large 
proteins with a resolution in the order of 10 Da and a preci- 
sion of less than 1 Da. Therefore, an increase of 80 Da pro- 
duced by the insertion of a single phosphate group can be 
easily detected. 
We have previously shown that different proportions of 
phospho and dephospho forms of a small peptide generate 
linear and proportional changes in the signal intensities ob- 
tained within the mass spectrometer, thus allowing quantita- 
tive monitoring of changes in the phosphorylation state of the 
peptide in vitro [4]. 
The peptide studied corresponded to the aa 39-51 sequence 
of a large protein, B-50/GAP-43 (226 aa in rat), which con- 
tains a phospho site for protein kinase C (PKC) on Ser-41. 
There is currently much debate on the role of B-50/GAP-43 in 
CNS function and particularly on its role in synaptic plasticity 
[5,6]. It has been proposed that in the induction phase of long- 
term potentiation (LTP, a cellular model for synaptic plastic- 
ity underlying learning and memory), an increased phosphor- 
ylation state of B-50/GAP-43 is observed and this increase 
could in turn induce an enhancement in neurotransmitter r -
lease [7,8]. Moreover, it has been observed that LTP induction 
in hippocampal slices increases the phosphorylation state of 
another PKC substrate, neurogranin (BICKS, RC3) [8]. This 
protein is composed of only 78 aa in rats and shares a se- 
quence homology with B-50/GAP-43 limited to 15-19 amino 
acids which includes the PKC phospho site [9,10]. These two 
PKC substrates, however, show a differential localization in 
the CNS, B-50/GAP-43 being localized exclusively in the pre- 
synaptic ompartment [11] whereas neurogranin is localized in 
the perikarya nd dendrites of neurons [12]. Therefore, inves- 
tigation of changes in the phosphorylation state in vivo of 
both proteins might provide important clues for understand- 
ing the pre- and post-synaptic molecular mechanisms respon- 
sible for cognitive functions in normal and pathological con- 
ditions. 
Previous studies have described ES/MS analysis of B-50/ 
GAP-43 [13] and neurogranin [10]. The proteins were exten- 
sively purified from large amounts of bovine brain and their 
structures characterized. However, the methods described o 
not allow one to measure in the same sample the ratio of 
phospho vs dephospho forms of both proteins, mainly be- 
cause of the extraction procedure utilized, which, in the case 
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Fig. 1. Proteins in the extracts of rat cortex and hippocampus: ilver staining, autoradiograph of SDS-PAGE and immunoblots. A: Proteins 
present in crude hippocampal (H) and cortical (C) perchloric acid extracts were subjected to SDS-PAGE (15%) and gels silver stained. B: Cor- 
tical (C) and hippocampal (H) PCA extracts were incubated in the presence of purified PKC and [7-a2P]ATP, run on 15% polyacrylamide gel, 
0.1% SDS and phosphoproteins detected by autoradiography. The migration of molecular weight markers is indicated. Purified and radiola- 
belled B-50 run in a separated lane (solid arrowhead). Position of neurogranin is indicated by open arrowhead. C: Approx. 1 gg of total pro- 
teins from extracts were subjected to 15% SDS-PAGE and transferred on nitrocellulose paper. Hippocampal (H) and cortical (C) extract were 
immunostained with NM2 monoclonal antibody (B-50, solid arrowhead; neurogranin, open arrowhead). 
of B-50/GAP-43, leads to the loss of the major PKC phospho 
site [13]. Moreover, bovine B-50/GAP-43 and neurogranin 
show important  differences with the rat proteins in their ami- 
no acid sequence [10,13]. 
In this report, we describe a simple extraction procedure 
based upon the previously reported solubility of B-50/GAP- 
43 and neurogranin in perchloric acid (PCA) [14,15], thus 
allowing for their simultaneous detection in individual rat 
brain areas (cortex and hippocampus) together with their re- 
spective phospho forms. Moreover, we show that B-50/GAP- 
43, bearing numerous phosphorylatable sites, appears to be 
largely present in its monophosphorylated form in rat brain. 
2. Materials and methods 
2.1. Materials 
Calmodulin agarose gel (phosphodiesterase 3',5'-cyclic nucleotide 
activator-agarose), diolein (DL-glycero1 ,2-dioleate), horse heart myo- 
globin and L-a-phosphatidylserine (PS) from bovine brain were ob- 
tained from Sigma (Italy). Gel filtration columns (P6, Bio-Gel DG 10 
and P30) were obtained from Bio-Rad (Italy). [7-a2P]ATP (spec. act. 
3000 Ci/mmol) was from Amersham Corp. (Italy) 
2.2. PCA extraction 
Cortex and hippocampus from rat brain were rapidly dissected and 
homogenized in 2.5% PCA [14] (1 g tissue/5 ml) and centrifuged at 
34000 x g for 60 min. The pellet was discarded and the supernatant 
immediately neutralized with a minimal volume of a saturated solu- 
tion of (NH4)2CO3. The supernatants were then desalted on a P6 
column and concentrated in a Speed Vacuum Savant centrifuge and 
stored at -20°C until analyzed by either SDS-PAGE or ES/MS. Pro- 
tein concentrations in each sample were measured according to Brad- 
ford [16], using BSA (Sigma, Italy) as standard. 
2.3. Protein phosphorylation assay 
To identify PKC substrates in the PCA extracts, proteins were 
phosphorylated in vitro in a post-hoc assay with purified PKC [17], 
as previously described [18]. Phosphorylated proteins were then sub- 
jected to discontinuous SDS-PAGE (running gel: 15% unless indi- 
cated differently in the text). Gels were stained, destained and auto- 
radiographed (Hyperfilm, Amersham, Italy) as previously described. 
B-50 purified following the method described by De Graan et al. [19] 
was utilized as control. 
2.4. lmmunoblotting 
Proteins present in PCA extracts were separated in SDS-PAGE on 
a 15% running gel, transferred electrophoreticallly to nitrocellulose 
and immunoincubated with the primary antibody (NM2, monoclonal 
antibody recognizing both B-50 and neurogranin; dilution 1:2000, 
kind gift of Dr. De Graan) according to Oestreicher et al. [20]. 
2.5. HPLC-ESIMS 
Approx. 20-100 ng of total proteins in the extract were applied to a 
perfusion microcolumn (Fus-15-R2/H; i.d. 300 gin, length 15 cm, LC- 
Packings, The Netherlands) coupled to an HPLC (HP 1090, series II, 
Hewlett-Packard, Palo Alto, USA). The sample was applied in 8 gl of 
buffer A (H20/CH3COOH 2%/TFA 0.01°/dCHaCN 2%) and eluted 
with a gradient of buffer B (CH3CN 98°/dCH3COOH 2%/TFA 0.01%) 
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Fig. 2. Total ion chromatogram of a cortical PCA extract. 8 gl of a 
neutralized and desalted cortical extract were injected into HPLC- 
ES/MS and the total ion current chromatogram was recorded 
throughout the elution from the microcolumn. The ordinate indi- 
cates the abundance (arbitrary units) of the ions generated by the 
molecular species present in the mixture. Similar chromatograms 
were obtained from hippocampal extracts. 
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Fig. 3. Electrospray mass spectrum of B-50 in PCA extract. A: Raw mass spectrum was recorded at 27.0 min of elution from the HPLC col- 
umn. B: Clusters of multiply charged related peaks generated by ionization of a protein of MW 23 602.64 + 2.6, corresponding to dephospho- 
B-50/GAP-43. C: Cluster of related peaks corresponding to monophospho-B-50/GAP-43: calculated MW 23 672.88 + 10.66. 
as follows: isocratic 3min, 0-5% B 5 min, 5-70% B 20 min, 70-100% 
B 10 min, and a final isocratic phase 100% B for 40 min, at a flow rate 
of 50 kd/min. Preconcentration at the head of the column was used in 
order to allow injection of this volume into the microcolumn. The 
HPLC column was connected on line with an HP 5989 B mass spec- 
trometer consisting of an electrostatic ion source operating at atmo- 
spheric pressure (API/ES/MS 59987 A-HP, Hewlett-Packard, Palo 
Alto, USA) followed by a quadrupole mass analyzer with a mass 
range of 0-2000 arbitrary mass units (amu). Calibration was per- 
formed using the multiply charged ions from a separate introduction 
of horse heart myoglobin (16950.5 Da). Deconvolution of charged 
ions present in raw mass spectra was performed applying an algo- 
rithm included into the standard ES/MS software installed on a VEC- 
TRA 486 33 U-HP (Hewlett-Packard, Palo Alto, USA) computer 
system. Values of the molecular masses are given as 'average mass 
(compound mass)' + S.D. 
3. Resul ts  
3.1. PKC subtrates in extracts from brain areas 
Proteins in PCA extracts were subjected to SDS-PAGE and 
the gels were silver stained (Fig. 1A). To identify PKC sub- 
strates, aliquots of the extracts were in vitro phosphorylated 
with the purified kinase. At least four phosphoprotein bands 
were found in the cortical and hippocampal extracts with 
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Fig. 4. Electrospray mass spectrum of neurogranin. Deconvolution 
of clusters present in the mass spectrum recorded at 14.2 min gives 
two molecular species differing by 83.6 Da. The peak at 7450.97 
corresponds to dephosphoneurogranin and that at 7534.61 to the 
phosphorylated form of the protein. The abundance of the phospho 
form (right ordinate) is 2.7-fold greater than that of the depho- 
sphorylated form (left ordinate). 
estimated Mr values of about 78 000, 47 000, 21 000 and 17 000 
(Fig. 1B). Among them, B-501GAP-43 and neurogranin have 
been unequivocably identified by western blot analysis of the 
same gel using a monoclonal antibody (NM2 [20]) recognizing 
both proteins (Fig. 1C). 
The extraction procedure yields 20-25 ~tg of total proteins 
from 100 mg of tissue. The recovery of the extraction proce- 
dure was evaluated by adding 32p-labelled B-501GAP-43 in 
the homogenate. All radiolabelled B-501GAP-43 (95 _+ 3.3%) 
was found in the extract. 
3.2. HPLC-ES/MS analysis o f  brain extracts 
PCA extracts were analyzed with capillary microcolumn 
HPLC-ES/MS, and mass spectra were continuously recorded 
throughout the elution from the HPLC column. A represen- 
tative total ion current chromatogram of a tissue extract is 
reported in Fig. 2. 
The mass spectrum recorded at the elution time of 27.0 min 
is shown in Fig. 3A. Its deconvolution generates two major 
clusters of related peaks, corresponding to two molecular spe- 
cies with a calculated average mass of 23 602.64 + 2.6 mass 
units (m.u.) and 23672.88+ 10.66 m.u. (6 separate xperi- 
ments using individual cortical and hippocampal extracts of 
6 animals each). The expected MW of rat dephospho B-50I 
GAP-43 is 23 602, which is coincident with that found in the 
extracts. The MW of the other species differs by about 80 
mass units, when taking into account he SD of the calculated 
value. Considering that it elutes from the HPLC column with 
the same retention time, we can conclude that it corresponds 
to the monophospho f rm of B-501GAP-43. 
The mass spectrum of Fig. 3A shows other clusters of re- 
lated peaks with small differences in mass units but with lower 
intensities, suggesting that B-501GAP-43 obtained from rat 
brain tissue is present in several post-translational modifica- 
tions, most likely in several phosphorylation states. However, 
the low intensity of these signals does not allow for a correct 
and accurate mass assignment. 
Mass spectrometric analysis of the same cortical extract 
where B-501GAP-43 is present, also reveals the presence of 
neurogranin at the elution time of 14.2 min. Deconvolution 
of the raw mass spectrum (not shown) identifies two clusters 
of related peaks corresponding to two molecular species of 
7450.97 + 5.3 and 7534.61 + 4.8 m.u. (Fig. 4). The mass differ- 
ence of about 80 Da again suggests the presence of dephospho 
and monophospho f rms of neurogranin. No other clusters of 
peaks can be detected indicating, as expected, only a single 
post-translational modification. The recorded MW is in good 
agreement with the theoretical MW of neurogranin calculated 
from cDNA (7495.0 Da) showing a difference lower than 
0.5%. Identical results have been obtained in hippocampal 
extracts (data not shown). 
4. Discussion 
In view of the relevant role of phosphorylation processes in 
the CNS [1], the direct measurement of the phosphorylation 
state of protein substrates i of great biological importance. 
We focussed our attention upon two PKC substrates, B-50/ 
GAP-43 and neurogranin, because both proteins have been 
suggested to be involved in activity-dependent synaptic plas- 
ticity and changes in their phosphorylation state might be one 
of the biochemical mechanisms underlying these processes 
[7,8]. However, their in vivo phosphorylation state has be 
inferred through indirect measurements utilizing radioenzy- 
matic procedures involving incorporation of 32p in vitro. We 
now show that in rat cortex and hippocampus B-501GAP-43 
and neurogranin are present as phosphoproteins in vivo, uti- 
lizing a simple extraction procedure and HPLC-ESIMS. 
Although previous studies reported ES/MS data for B-50/ 
GAP-43 [13] and neurogranin [10], they failed to show that: 
(i) phospho-neurogranin is present with its dephospho form in 
tissue extracts and (ii) B-501GAP-43 monophospho f rm is by 
far the predominant phospho form in rat brain tissue. Indeed, 
B-501GAP-43 seems to contain, in addition to the PKC phos- 
pho site at Ser-41, additional phosphosites at Ser-96 and at 
Thr-172 in the rat sequence [21]. The physiological relevance 
of these phospho sites in vivo is not yet fully characterized. 
On the other hand the key role played by PKC phospho site 
Ser-41 has been clarified further in mutant GAP-43 overex- 
pressing mice, where the protein cannot be phosphorylated by
PKC and the sprout-promoting activity has been profoundly 
depressed [22]. Additional experiments, to prove that the pre- 
dominant monophospho f rm of B-501GAP-43 in rat brain is 
at Ser-41, are required and we are currently testing whether 
stimulating PKC activity in rat brain, known to phosphory- 
late Ser-41, is able to increase the peak intensity of the phos- 
pho vs that of the dephospho form. 
The extraction procedure described here takes advantage of 
the fact that both B-50/GAP-43 and neurogranin, together 
with another small number of proteins (Fig. 1A), are soluble 
in 2.5% vPCA [14,15] and are efficently extracted from brain 
tissue. 
Although we do not have direct proof of the efficency of 
M. Di Luca et al./FEBS Letters 389 (1996) 309-313 313 
extraction for neurogranin under our experimental conditions, 
it is reasonable to assume that this much smaller protein, with 
biochemical characteristics similar to those of B-50/GAP-43, 
is also efficently extracted in both its phospho and dephospho 
forms. In any event, since the biological activity of the protein 
is due to changes in the ratio of the phospho vs its dephospho 
form and since both species are simultaneously detected in the 
same extract, any in vivo change of this ratio should be de- 
tectable by ES/MS. Preliminary experiments in hippocampal 
slices treated with PKC activators, like phorbol esters, indeed 
show an increase in the ratio of the phospho vs dephospho 
form of neurogranin. 
Finally, it should be noted that the measured MW of rat B- 
50/GAP-43 is identical to that expected on the basis of its 
sequence: the previous tudy on bovine B-50/GAP-43 showed 
a difference of more than 380 Da [13]. For neurogranin we 
have obtained a difference of less than 0.5% in the measured 
MW vs the expected one, whereas in bovine brain the differ- 
ence reported is more than 8% [10]. 
In conclusion, we show that it is possible to detect and 
measure the ratio of the phosphorylation state of two PKC 
substrates, B-50/GAP-43 and neurogranin, in single rat brain 
areas where these proteins seem to exert important biological 
functions. Limited information is available about the tempo- 
ral activation of PKC in the two neuronal compartments dur- 
ing LTP. Since B-50 and neurogranin are specific pre- and 
post-synaptic substrates for PKC in hippocampus, the direct 
measurement of the phosphorylation state of these two pro- 
teins during the induction and maintenance of LTP will con- 
tribute to clarification of the relative importance of PKC iso- 
forms and their location in this form of activity-dependent 
synaptic plasticity. 
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